A Better Diabetes Drug?

Amylin shares fell more than 8 percent on Monday after data from an important diabetes meeting sparked concern about competition to the company's flagship Byetta medicine which Amylin sells with Eli Lilly .

Byetta has been the only drug on the market in the GLP-1 class of medicines that stimulate the release of insulin only when glucose levels become too high. They also lead to modest weight loss, which is seen as an advantage over other types of diabetes medicines, because obesity is a leading cause of the disease.

The drop continued a slide for Amylin, which fell more than 8 percent on Friday after Novo Nordisk released data showing its experimental drug liraglutide outperformed Byetta in a clinical trial.

I’d still watch Amylin, counsels Pete Najarian. They’re working on a once-a-week treatment for diabetes and if they have positive results the stock could surge.

Got something to to say? Send us an e-mail at fastmoney-web@cnbc.com and your comment might be posted on the Rapid Recap. If you'd prefer to make a comment but not have it published on our website send your e-mail to fastmoney@cnbc.com.

Trader disclosure: On June 9, 2008, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders; Macke Owns (EMC), (ATVI), (INTC), (WMT), (MSFT), (DIS); Pete Najarian Owns (AAPL), (BKC), (TSO), (XLF), (HPQ), (AMLN); Pete Najarian Owns (AA) Calls, (GME) Calls; Pete Najarian Owns (LEH) Puts; Finerman Owns (GS); Finerman's Firm Owns (AAPL), (MSFT), (TSO), (VLO); Finerman's Firm And Finerman Own (C) And (C) Leaps; Finerman's Firm Owns SPX Index Puts; Finerman's Firm Is Short (IYR), (IJR), (MDY), (SPY), (IWM); Seymour Owns (AAPL), (AA), (INTC), (MER), (TIE), (TSO), (F); Seygem Asset Management Owns (EEM), (HAL), (TTM), (MBT), (GAF)